Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11426 - 11450 of 12759 in total
RR001 is an investigational gene therapy consisting of autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand (AD-PC sTRAIL).
Investigational
P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.
Investigational
Bersanlimab is an investigational monoclonal antibody directed against intercellular adhesion molecule 1 (ICAM-1).
Investigational
Saposin C is a lysosomal protein. Recombinant, non-glycosylated Saposin C is an active ingredient of BXQ-350, which is a novel, investigational anti-neoplastic therapy. BXQ-350 consists of Saposin C and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes.
Investigational
Experimental
Investigational
Investigational
Gemogenovatucel-T is a bi-shRNA furin/Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented autologous tumour cell vaccine. Furin is a convertase involved in the activation of TGFβ-1 and TGFβ-2. Gemogenovatucel-T is being investigated in the treatment of various cancers.
Investigational
SCH-58500 is a recombinant replication-deficient adenovirus vector carrying the human p53 gene.
Investigational
Investigational
KAHR-102 is a dual signaling protein fusing cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to the Fas-ligand (FasL).
Investigational
Investigational
Investigational
BSK02 is a Sperm Protein-17 oral microparticle vaccine
Investigational
L-3972-T is one of the components of the human papilloma virus (HPV) type 16 E6/E7 synthetic long peptide (SLP) vaccine ISA101b.
Investigational
Mecbotamab vedotin is an anti-Axl humanized monoclonal antibody conjugated to monomethyl auristatin E using a cleavable linker (CAB-Axl-ADC).
Investigational
Linvoseltamab is an investigational bispecific antibody. It promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells.
Investigational
Investigational
MK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT) 3.
Investigational
MK-4830 is a monoclonal antibody that targets the myeloid-specific immunoglobulin-like transcript (ILT) 4 receptor.
Investigational
RO-7293583 is a TYRP1-Targeting CD3 T-Cell Engager.
Investigational
The gp209-2M antigen is derived from gp209, and has potential immunomodulatory and antineoplastic activities.
Investigational
Displaying drugs 11426 - 11450 of 12759 in total